Literature DB >> 10524926

Urinary cytokines as markers of reflux nephropathy.

G K Ninan1, R S Jutley, O Eremin.   

Abstract

PURPOSE: We established whether the urinary cytokines interleukin-6 (IL-6), tumor necrosis factor (TNF)-alpha and soluble TNF receptor-1 have a role as noninvasive markers of renal damage in children with vesicoureteral reflux.
MATERIALS AND METHODS: We performed an observational study in a surgical and urological unit at a pediatric teaching hospital. Urine cytokine levels of IL-6, TNF-alpha and soluble TNF receptor-1 were measured using a standard enzyme-linked immunosorbent assay technique in children stratified into group 1--11 with vesicoureteral reflux and reflux nephropathy, group 2--6 with vesicoureteral reflux only and no associated nephropathy, and group 3--15 age and sex matched controls.
RESULTS: Urinary levels of the cytokines IL-6 and soluble TNF receptor-1 were significantly elevated in group 1 versus group 3 (0.048 to 13.25 pg./micromol. creatinine, mean 3.658 versus 0.027 to 0.677, mean 0.247 and 102.89 to 4,502.9 pg./micromol. creatinine, mean 1,395.3 versus 13.06 to 569.6, mean 145.357, respectively). Neither cytokine in group 2 (0.074 to 10.96 pg./micromol. creatinine, mean 2.94 and 51.52 to 1,115.48, mean 413.137, respectively) was elevated compared to that in group 3. TNF-alpha was not elevated in group 1 or 2 compared to that in group 3 (0.104 to 2.518 pg./micromol. creatinine, mean 0.56, 0.094 to 1.278, mean 0.334 and 0.065 to 0.694, mean 0.241, respectively).
CONCLUSIONS: Measuring the urinary levels of the cytokines IL-6 and soluble TNF receptor-1 may be useful as a noninvasive marker of reflux associated renal damage. Further studies with larger patient groups are necessary to locate the source of production of the elevated urinary cytokines measured in our study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524926

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Differential profile analysis of urinary cytokines in patients with overactive bladder.

Authors:  Gamal Ghoniem; Nuzhat Faruqui; Mostafa Elmissiry; Ayman Mahdy; Hassan Abdelwahab; Mathew Oommen; Asim B Abdel-Mageed
Journal:  Int Urogynecol J       Date:  2011-04-13       Impact factor: 2.894

2.  Urine IL-8 concentrations in infectious and non-infectious urinary tract conditions.

Authors:  Maria Bitsori; Maria Karatzi; Helen Dimitriou; Eleni Christakou; Avrora Savvidou; Emmanouil Galanakis
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

3.  Urinary levels of interleukin-6 and interleukin-8 in patients with vesicoureteral reflux and renal parenchymal scar.

Authors:  Ibrahim Gokce; Harika Alpay; Nese Biyikli; Goksenin Unluguzel; Fuat Dede; Ahmet Topuzoglu
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

4.  Autologous fibroblast transplantation at the vesico-ureteral junction as potential reconstructive cell replacement in an animal model.

Authors:  Renate Pichler; Guenter Klima; Elisabeth Richter; Rainer Marksteiner; Viktoria Mayr; Viktor Skradski; Wolfgang Horninger; Josef Oswald
Journal:  World J Urol       Date:  2012-08-04       Impact factor: 4.226

5.  Vesicourethral reflux in pediatrics with hypermobility syndrome.

Authors:  Fatemeh Beiraghdar; Zohreh Rostami; Yunes Panahi; Behzad Einollahi; Mojtaba Teimoori
Journal:  Nephrourol Mon       Date:  2013-08-12

6.  Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study.

Authors:  Zainab Khan; Gareth D Healey; Roberta Paravati; Nidhika Berry; Eugene Rees; Lavinia Margarit; Deyarina Gonzalez; Simon Emery; Robert Steven Conlan
Journal:  Front Cell Infect Microbiol       Date:  2021-09-30       Impact factor: 5.293

Review 7.  Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease.

Authors:  Ana Cristina Simões e Silva; Flávia Cordeiro Valério; Mariana Affonso Vasconcelos; Débora Marques Miranda; Eduardo Araújo Oliveira
Journal:  Clin Dev Immunol       Date:  2013-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.